ストックスクリーナーアプリを入手
3.02
0.33%
0.01
前日終値:
$3.01
開ける：
$3.02
24時間の取引高:
153.77K
Relative Volume:
0.88
時価総額：
$95.80M
収益：
-
当期純損益:
$-98.79M
株価収益率:
-0.7056
EPS:
-4.28
ネットキャッシュフロー:
$-51.66M
1週間 パフォーマンス:
-7.08%
1か月 パフォーマンス:
-16.34%
6か月 パフォーマンス:
-9.58%
1年 パフォーマンス:
+7.86%
1日の値動き範囲:
$2.9761
$3.22
1週間の範囲:
$2.96
$3.425
52週間の値動き範囲:
$1.88
$7.2225
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| RLMD | 3.03 | 0 | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics initiates Phase 1 dosing with REL-P11 - TipRanks
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease - The Manila Times
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Relmada Therapeutics reports Q3 financials, focuses on REL-1017 - Investing.com Nigeria
Relmada Therapeutics hopes to hit big milestones by year-end - Green Market Report
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights - GuruFocus.com
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance UK
Relmada Therapeutics Inc. Reports Q3 2024 Financial Results - TipRanks
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - Quantisnow
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
Relmada Therapeutics (RLMD) Set to Announce Earnings on Thursday - MarketBeat
3 US Penny Stocks To Monitor In October 2024 - Simply Wall St
Q3 Earnings Estimate for RLMD Issued By Leerink Partnrs - MarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Purchased by Renaissance Technologies LLC - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 0.3%Should You Sell? - MarketBeat
Roblox Corp general counsel sells $774,810 in stock By Investing.com - Investing.com Canada
Roblox Corporation [RBLX] moved down -1.09: Why It’s Important - The DBT News
RBLX (Roblox Corporation) may reap gains as insiders became active recently - Knox Daily
Hancock Whitney Corp Reduces Stake in Relx Plc (NYSE:RELX) - Defense World
Bet on a Slow March Higher in Roblox (NYSE:RBLX) Stock with a Credit Spread - Nasdaq
RELX rises Monday, outperforms market - MarketWatch
Relx Plc (NYSE:RELX) Shares Bought by Mercer Global Advisors Inc. ADV - Defense World
Financial Health Report: Relmada Therapeutics Inc (RLMD)’s Ratios Tell a Tale - The Dwinnex
What's Going On With Richtech Robotics Stock? - Benzinga
Relx (NYSE:RELX) Hits New 12-Month High at $48.32 - MarketBeat
A new trading data show Relmada Therapeutics Inc (RLMD) is showing positive returns. - SETE News
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - Defense World
Understanding the Risks of Investing in Relmada Therapeutics Inc (RLMD) - Knox Daily
Why ResMed Stock Tumbled by 5% Today - The Motley Fool
Monitoring Collegium Pharmaceutical Inc (COLL) after recent insider movements - Knox Daily
Is Marvell Technology, Inc. (MRVL) The Worst 5G Stock to Buy According to Short Sellers? - Yahoo Finance
Relmada Therapeutics (NASDAQ:RLMD) Raised to Buy at Jefferies Financial Group - MarketBeat
Relmada Therapeutics Inc Inc. (RLMD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Relmada stock jumps as Jefferies upgrades (NASDAQ:RLMD) - Seeking Alpha
Relmada stock's "risk/reward setup" could lead to big upsideJefferies - Investing.com
Finansavisen - Finansavisen
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - PR Newswire
Relmada Therapeutics Inc (RLMD) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Insider Spends US$395k Buying More Shares In Relmada Therapeutics - Yahoo Finance
Relmada Therapeutics CFO buys $149,700 in company stock - Investing.com India
Analyst sustains stock target, outperform on Relmada amid insider buys - Investing.com India
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) - Yahoo Finance
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Th - GuruFocus.com
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) By GuruFocus - Investing.com Canada
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140 - GuruFocus.com
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares By GuruFocus - Investing.com Canada
Relmada Therapeutics director buys $33,280 in company stock - Investing.com India
Relmada therapeutics CEO acquires shares worth over $395k - Investing.com India
Relmada Therapeutics director buys $33,280 in company stock By Investing.com - Investing.com Canada
Insider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Buys 8,194 Shares of Stock - MarketBeat
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares - Yahoo Finance
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):